ARTÍCUL
O ESPECIAL
The Influence of
Sex Hormones on Cardiovascular Health: Current Perspectives and Future
Directions
La influencia de las hormonas sexuales en
la salud cardiovascular: perspectivas actuales y direcciones futuras
Kirolos Eskandar 1,a
1
Johannes Diakonie Klinik, Mosbach, Germany.
a
Bachelor’s of Medicine and Surgery (MBBCh).
Cite
as: Eskandar
K. The Influence of Sex Hormones on Cardiovascular Health: Current Perspectives
and Future Directions. Rev Peru Cienc Salud. 2024; 6(2). doi:
https://doi.org/10.37711/rpcs.2024.6.2.449
Received:
13/12/23
Accepted: 26/02/24
Published online: 02/04/24
ABSTRACT
The
intricate relationship between sex hormones and cardiovascular health has
garnered increasing attention, revealing significant implications for both
disease prevention and therapeutic strategies. This literature review aims to
elucidate the multifaceted roles of estrogen, progesterone, and testosterone in
cardiovascular physiology and pathology. Estrogen is widely recognized for its
protective effects on vascular function, lipid metabolism, and atherosclerosis
prevention, while testosterone presents a more complex picture with both
beneficial and detrimental impacts on cardiovascular risk. Progesterone, often
overlooked, also plays a critical role in modulating these effects.
Additionally, this review explores how sex hormones influence endothelial
function, inflammatory responses, and contribute to gender differences in
cardiovascular disease prevalence. The impact of menopause and hormone
replacement therapy (HRT) on cardiovascular health is critically examined,
highlighting ongoing debates and current guidelines. Furthermore, the
cardiovascular implications of gender-affirming hormone therapy in transgender
individuals are discussed. By synthesizing current perspectives, incorporating
recent studies up to 2023, and identifying future research directions, this
review underscores the potential for personalized medicine approaches that
consider genetic, environmental, and lifestyle factors, as well as healthcare
equity, to optimize cardiovascular health outcomes.
Keywords:
Sex hormones, Cardiovascular health, Estrogen, Testosterone, Hormone
replacement therapy, Personalized medicine, Healthcare equity (Source: MeSH - NLM).
RESUMEN
La intrincada relación entre las
hormonas sexuales y la salud cardiovascular ha atraído cada vez más atención,
revelando implicaciones significativas tanto para la prevención de enfermedades
como para las estrategias terapéuticas. Esta revisión de la literatura tiene
como objetivo dilucidar las funciones multifacéticas de los estrógenos, la
progesterona y la testosterona en la fisiología y patología cardiovascular. El
estrógeno es ampliamente reconocido por sus efectos protectores sobre la
función vascular, el metabolismo de los lípidos y la prevención de la aterosclerosis, mientras que la testosterona presenta
un cuadro más complejo con impactos tanto beneficiosos como perjudiciales sobre
el riesgo cardiovascular. La progesterona, que a menudo se pasa por alto,
también desempeña un papel fundamental en la modulación de estos efectos.
Además, esta revisión explora cómo las hormonas sexuales influyen en la función
endotelial, las respuestas inflamatorias y contribuyen a las diferencias de
género en la prevalencia de enfermedades cardiovasculares. Se examina
críticamente el impacto de la menopausia y la terapia de reemplazo hormonal
(TRH) en la salud cardiovascular, destacando los debates en curso y las pautas
actuales. Además, se discuten las implicaciones cardiovasculares de la terapia
hormonal de afirmación del género en personas transgénero.
Al sintetizar las perspectivas actuales, incorporar estudios recientes hasta
2023 e identificar futuras direcciones de investigación, esta revisión subraya
el potencial de los enfoques de medicina personalizada que consideran factores
genéticos, ambientales y de estilo de vida, así como la equidad en la atención
médica, para optimizar los resultados de salud cardiovascular.
Palabras clave: Hormonas
sexuales, Salud cardiovascular, Estrógeno, Testosterona, Terapia de reemplazo
hormonal, Medicina personalizada, Equidad en la atención médica (Fuente: DeCS - BIREME).
INTRODUCTION
Cardiovascular
disease (CVD) remains a leading cause of morbidity and mortality worldwide,
posing a significant public health challenge (1). While traditional
risk factors such as hypertension, dyslipidemia, and smoking are
well-established, emerging evidence suggests that sex hormones play a crucial
role in modulating cardiovascular health (2). Estrogen,
progesterone, and testosterone, traditionally associated with reproductive
functions, exert diverse effects on the cardiovascular system (3).
Understanding the intricate interplay between these hormones and cardiovascular
physiology is essential for elucidating sex disparities in CVD incidence,
presentation, and outcomes (4).
Estrogen,
primarily synthesized in the ovaries, exerts vaso
protective effects by promoting endothelial nitric oxide synthase (eNOS) expression and enhancing endothelial function, which
involves the regulation of vascular tone, blood flow, and the balance between
coagulation and fibrinolysis(5).Experimental studies have
demonstrated estrogen's ability to attenuate vascular inflammation, inhibit
smooth muscle cell proliferation, and enhance high-density lipoprotein (HDL)
cholesterol levels, collectively reducing atherosclerotic burden (6).
Moreover, estrogen receptors are expressed in various cardiovascular tissues,
suggesting direct cardio protective mechanisms independent of its effects on
lipid metabolism and blood pressure regulation (7).
In
contrast, testosterone, predominantly produced in the testes, exhibits
divergent effects on cardiovascular risk. While testosterone may confer cardio
protective benefits by improving insulin sensitivity, enhancing skeletal muscle
mass, and reducing visceral adiposity (8, 9), it is also implicated
in promoting proathero genic processes such as
endothelial dysfunction, arterial stiffness, and thrombosis (10, 11).
The complex relationship between testosterone and cardiovascular health
underscores the importance of considering sex-specific effects and hormone
balance in disease risk assessment and management.
Progesterone,
often overshadowed by estrogen and testosterone, exerts regulatory effects on
vascular tone, inflammation, and thrombosis (12). Progesterone
receptors are expressed in endothelial cells, smooth muscle cells, and cardiomyocytes, suggesting a direct influence on
cardiovascular function (13). Emerging evidence suggests a potential
role for progesterone in modulating the cardiovascular effects of estrogen and
testosterone, highlighting its significance in sex hormone-mediated cardioprotection.
Despite
advances in our understanding of sex hormone-mediated cardiovascular effects,
several challenges remain. Menopause, characterized by declining estrogen
levels, is associated with an increased risk of CVD, prompting debates
regarding the cardiovascular safety and efficacy of hormone replacement therapy
(HRT) (14, 15). Furthermore, the cardiovascular implications of
gender-affirming hormone therapy in transgender individuals warrant further
investigation to optimize risk assessment and management strategies (16).
In
this literature review, we aim to provide a comprehensive overview of the
current perspectives on the influence of sex hormones on cardiovas-
cular health. By synthesizing existing evidence,
incorporating recent studies up to 2023, and identifying future research
directions, we seek to enhance our understanding of sex-specific cardio-
vascular risk factors and facilitate the development of personalized
therapeutic approaches that consider genetic, environmental, and lifestyle
factors, as well as addressing healthcare disparities.
DEVELOPMENT
Estrogen
and cardiovascular protection
Estrogen,
a pivotal sex hormone primarily synthesized in the ovaries, plays a critical
role in cardiovascu- lar physiology, exerting
multifaceted effects that contribute to its protective role against
cardiovascular diseases (17). Mechanistically, estrogen influences
various aspects of vascular function, lipid metabolism, blood pressure
regulation, and atherosclerosis development. These effects are mediated through
both genomic and non-genomic mechanisms, involving estrogen receptors
abundantly expressed in cardiovascular tissues (18). Activation of
estrogen receptors leads to the regulation of gene transcription, resulting in
downstream effects on vascular homeostasis, inflammation, and oxidative stress.
Additionally, estrogen exerts rapid, non-genomic effects via membrane-bound
estrogen receptors, activating signaling pathways such as PI3K/Akt and MAPK/ERK, which modulate endothelial function and
vascular tone.
One
of the key mechanisms underlying estrogen's cardiovascular protection is its
ability to promote endothelial function. Estrogen enhances endothelial nitric
oxide synthase (eNOS) expression and activity,
leading to increased nitric oxide (NO) production (19). NO, a potent
vasodilator, regulates vascular tone, inhibits platelet aggregation, and
prevents smooth muscle cell proliferation, thereby maintaining vascular
homeostasis and preventing atherosclerosis (20). Furthermore,
estrogen attenuates endothelial dysfunction by inhibiting endothelin-1
production, reducing oxidative stress, and modulating endothelial progenitor
cell function.
Estrogen
also plays a crucial role in lipid metabolism, exerting favorable effects on
lipoprotein profiles. It increases high-density lipoprotein cholesterol (HDL-C)
levels while reducing low-density lipoprotein cholesterol (LDL-C) and
triglycerides (21). Estrogen promotes reverse cholesterol transport
by upregulating ATP-binding cassette transporters, facilitating cholesterol
efflux from macrophages and promoting its transport to the liver for excretion.
Moreover, estrogen inhibits the expression of proinflammatory
cytokines and adhesion molecules, thereby attenuating lipid oxidation,
inflammation, and atherosclerotic plaque formation (22).
In
terms of blood pressure regulation, estrogen exhibits complex effects,
demonstrating both vasodilatory and antihypertensive
properties (23). It enhances endothelial-dependent vasodilation,
inhibits the renin-angiotensin-aldosterone system, and modulates sympathetic
nervous system activity, collectively contributing to blood pressure
homeostasis. Furthermore, estrogen inhibits vascular smooth muscle cell
proliferation and migration, reducing neointimal
hyperplasia and attenuating atherosclerotic lesion formation (24).
The
comprehensive understanding of estrogen's multifaceted effects on
cardiovascular physiology provides insights into its potential therapeutic
implications for cardiovascular diseases. However, further elucidation of the
underlying mechanisms and clinical translation of these findings are essential
for the development of targeted therapeutic strategies to mitigate
cardiovascular risk.
Testosterone
and cardiovascular risk
Testosterone,
primarily synthesized in the testes, significantly influences cardiovascular
physiology and pathology, extending beyond its classical roles in male
reproductive functions and musculoskeletal development (25). Its
actions are mediated through androgen receptors expressed in cardiovascular
tissues, modulating gene transcription and intracellular signaling pathways.
Consequently, testosterone's effects encompass various cardiovascular
parameters, including blood pressure regulation, lipid metabolism,
inflammation, and vascular function.
Epidemiological
studies have unveiled associations between testosterone levels and
cardiovascular diseases (CVD) in both sexes. In men, low testosterone levels
correlate with an elevated risk of coronary artery disease (CAD), myocardial
infarction (MI), and heart failure. Conversely, in women, conditions
characterized by androgen excess, such as polycystic ovary syndrome (PCOS),
often exhibit adverse cardiovascular outcomes, including hypertension,
dyslipidemia, and atherosclerosis (26).
Testosterone's
impact on lipid metabolism is profound, influencing cholesterol synthesis,
transport, and metabolism. Testosterone deficiency in men is linked to
unfavorable lipid profiles, typified by decreased high-density lipoprotein
cholesterol (HDL-C) levels and elevated low-density lipoprotein cholesterol
(LDL-C) levels (27). Conversely, women with PCOS frequently
experience dyslipidemia and insulin resistance alongside androgen excess,
contributing to an increased risk of metabolic syndrome.
Understanding
the interplay between testosterone and cardiovascular health is crucial for
risk stratification and targeted interventions. While testosterone deficiency
in men underscores an elevated CVD risk, androgen excess in women, particularly
in conditions like PCOS, presents unique challenges in cardiovascular risk
management. Thus, elucidating the mechanistic underpinnings of
testosterone-mediated cardiovascular effects holds promise for tailored
therapeutic strategies aimed at mitigating cardiovascular risk in individuals
with hormonal imbalances.
Progesterone
and cardiovascular health
Progesterone,
a key sex hormone primarily produced in the ovaries, plays a crucial role in
reproductive physiology and has emerging implications in car- diovascular health (28). While traditionally
recognized for its role in regulating the menstrual cycle and supporting
pregnancy, progesterone exerts diverse effects on the cardiovascular system,
interacting intricately with estrogen to modulate vascular function,
inflammation, and thrombosis.
Progesterone
influences various aspects of cardiovascular physiology, including vascular
tone, endothelial function, and coagulation. Progesterone receptors are
expressed in vascular tissues, suggesting direct effects on vascular smooth
muscle cells and endothelial cells (29). Progesterone promotes
vasodilation by enhancing nitric oxide (NO) bioavailability and modulating
endothelial-derived factors, contributing to the maintenance of vascular
homeostasis (30). Moreover, progesterone exhibits antithrombotic
properties by inhibiting platelet aggregation and thromboxane A2 synthesis,
thereby attenuating thrombotic risk.
Progesterone
interacts dynamically with estrogen to modulate cardiovascular function. While
estrogen primarily exerts vasodilatory effects,
progesterone may counterbalance estrogen-induced vasodilation by promoting
vasoconstriction through its effects on vascular smooth muscle tone (31).
Furthermore, progesterone regulates estrogen receptor expression and activity,
influencing estrogen-mediated effects on lipid metabolism, inflammation, and
atherosclerosis. The intricate interplay between progesterone and estrogen
underscores the complexity of sex hormone regulation in cardiovascular health
and disease.
The
overall effects of progesterone on cardiovascular health remain complex and
context-dependent. While some studies suggest beneficial effects, such as
vasodilation and anti-inflammatory actions, others have implicated progesterone
in adverse cardiovascular outcomes, particularly in the context of hormone
replacement therapy (32,33). Furthermore, the effects of
progesterone may vary based on factors such as dose, duration of exposure, and
the presence of coexisting cardiovascular risk factors (34). Thus,
further research is warranted to elucidate the specific mechanisms underlying
progesterone's cardiovascular effects and its clinical implications for
cardiovascular risk stratification and management.
Sex
hormones and endothelial function
Sex
hormones, including estrogen and testosterone, exert profound effects on
endothelial function, playing pivotal roles in regulating vascular homeostasis
and cardiovascular health (35). Endothelial cells, lining the inner
surface of blood vessels, serve as key regulators of vascular tone,
inflammation, and thrombosis, and they actively respond to hormonal cues. Both
estrogen and testosterone influence endothelial function through intricate
mechanisms involving modulation of nitric oxide (NO) production, oxidative
stress, and vascular tone regulation (36).
Estrogen,
primarily synthesized in the ovaries, exerts vasoprotective
effects on endothelial cells, promoting vasodilation and inhibiting vascular
inflammation and thrombosis (37). Estrogen receptors, including
estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), are
expressed in endothelial cells, enabling direct genomic and non-genomic actions
of estrogen (38). Estrogen enhances endothelial NO synthase (eNOS) expression and activity, leading to increased NO production, a critical mediator of
vasodilation and vascular homeostasis. Additionally, estrogen suppresses the
expression of adhesion molecules and proinflammatory
cytokines in endothelial cells, thereby attenuating endothelial dysfunction and
atherosclerosis.
Conversely,
testosterone, predominantly synthesized in the testes, exhibits complex effects
on endothelialfunction, demonstratingbothvasodilatory
and vasoconstrictive actions. Testosterone receptors,
including androgen receptors, are expressed in endothelial cells, modulating
intracellular signaling pathways involved in NO production and vascular tone
regulation (39). Testosterone enhances eNOS
expression and NO production in endothelial cells under physiological
conditions, promoting vasodilation and maintaining vascular homeostasis.
However, in pathological states characterized by androgen excess or imbalance,
testosterone may exert detrimental effects on endothelial function,
contributing to endothelial dysfunction and cardio- vascular risk (40).
The
intricate interplay between estrogen and testosterone further influences endothelial
function and vascular tone regulation. Estrogen and testosterone may exert
opposing effects on endothelial NO production and vascular tone, highlighting
the importance of sex hormone balance in cardiovascular health (41).
Moreover, the effects of sex hormones on endothelial function may vary based on
factors such as hormone levels, receptor expression, and the presence of
coexisting cardio- vascular risk factors. Understanding the complex
interactions between sex hormones and endothelial function is essential for
elucidating their roles in cardiovascular physiology and disease pathogenesis.
Menopause,
hormone replacement therapy, and cardiovascular health
Menopauserepresentsacriticaltransition in awoman's life
characterized by the cessation of ovarian function and a decline in sex hormone
production, particularly estrogen and progesterone. This hormonal shift is
associated with significant changes in cardiovascular risk factors, including
alterations in lipid metabolism, vascular function, and inflammation,
culminating in an increased risk of cardiovascular disease (CVD)
post-menopause.
Hormone
replacement therapy (HRT) has long been advocated as a potential intervention
to mitigate the adverse cardiovascular effects associated with menopause (42).
Estrogen-based HRT, either alone or in combination with progestogens, aims to
alleviate menopausal symptoms and preserve bone health while potentially
conferring cardiovascular benefits. Estrogen replacement therapy has been shown
to improve lipid profiles, promote vasodilation, and attenuate endothelial
dysfunction, all of which contribute to a favorable cardiovascular risk profile
(42,43).
However,
the cardiovascular benefits of HRT remain the subject of debate, with
conflicting evidence from observational studies and randomized controlled
trials (RCTs). While observational studies have suggested a protective effect
of HRT against CVD, RCTs such as the Women's Health Initiative (WHI) have
reported an increased risk of cardiovascular events, including myocardial
infarction, stroke, and venous thromboembolism, particularly with the use of
estrogen plus progestin therapy (44).
Current
guidelines recommend individualized decision-making regarding the initiation of
HRT for menopausal symptom management, taking into account factors such as age,
menopausal status, cardiovascular risk profile, and personal preferences (45).
HRT initiation should be accompanied by a thorough assessment of cardiovascular
risk factors, including lipid levels, blood pressure, and family history of CVD
(46). Furthermore, HRT should be prescribed at the lowest effective
dose for the shortest duration necessary to achieve treatment goals, with
regular reevaluation of the benefits and risks.
Despite
the controversies surrounding HRT, it remains a valuable therapeutic option for
select menopausal women, particularly those experiencing severe menopausal
symptoms and at low cardiovascular risk. Ongoing research efforts aim to
elucidate the underlying mechanisms of HRT-related cardio- vascular effects and
identify subgroups of women who may derive the greatest benefit from HRT while
minimizing potential risks (47).
Sex
hormones and inflammation
Sex
hormones play intricate roles in modulating inflammatory responses, exerting
both pro- and anti-inflammatory effects that have significant implications for
cardiovascular health (48). Estrogen, primarily synthesized in the
ovaries, demonstrates anti-inflammatory properties by attenuating the
production of proinflammatory cytokines and
chemokines and enhancing the activity of anti-inflammatory mediators (49).
Estrogen receptors, including estrogen receptor alpha (ERα) and estrogen
receptor beta (ERβ), are expressed in immune cells, allowing direct
modulation of immune responses by estrogen. Estrogen suppresses the activation
of nuclear factor-kappa B (NF-κB) and
mitogen-activated protein kinase (MAPK) signaling pathways, thereby inhibiting
the expression of proinflammatory genes and
mitigating inflammatory responses.
Conversely,
testosterone, predominantly synthesized in the testes, exhibits complex effects
on inflammation, demonstrating both pro- and anti-inflammatory properties
depending on the context and target tissue (50). Testosterone
modulates immune cell function by regulating cytokine production, phagocytosis,
and T-cell proliferation, thereby influencing the balance between inflammatory
and anti-inflammatory responses. Testosterone's effects on inflammation are
mediated through androgen receptors expressed in immune cells, including
monocytes, macrophages, and lymphocytes (51). Testosterone may exert
anti-in- flammatory effects by inhibiting the
production of proinflammatory cytokines such as tumor
necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), while also
promoting the secretion of anti-inflammatory cytokines such as interleukin-10
(IL-10).
The
dysregulation of sex hormone-mediated inflammatory responses has been
implicated in the pathogenesis of chronic inflammatory conditions, including
atherosclerosis and cardiovascular disease (CVD) (52).
Postmenopausal women, characterized by declining estrogen levels, exhibit a proinflammatory phenotype associated with increased
circulating levels of proinflammatory cytokines and
acute-phase proteins. Conversely, conditions characterized by androgen excess,
such as polycystic ovary syndrome (PCOS), are associated with chronic low-grade
inflammation and an increased risk of cardiovascular complications.
Understanding
the complex interplay between sex hormones and inflammation is essential for
unraveling the mechanisms underlying cardiovascular disease pathogenesis and
identifying potential therapeutic targets. In the subsequent section, we will
explore the interconnections between sex hormones, inflammation, and vascular
dysfunction, further elucidating their roles in cardiovascular health and
disease.
Gender
differences in cardiovascular disease
Cardiovascular
disease (CVD) exhibits striking differences between men and women in terms of
epidemiology, pathophysiology, and clinical presentation (53).
Historically, CVD has been considered predominantly a male disease, leading to underrecognition and undertreatment
of CVD in women. However, epidemiological studies have highlighted significant
gender disparities in the prevalence, risk factors, and outcomes of CVD,
emphasizing the need for gender-specific approaches to cardiovascular risk
assessment and management (54).
Men
have traditionally been perceived to be at higher risk for CVD compared to
women, particularly at younger ages (55). Men tend to present with
CVD at an earlier age and have a higher incidence of coronary artery disease
(CAD), myocardial infarction (MI), and sudden cardiac death. The influence of
sex hormones, including testosterone, on traditional cardiovascular risk
factors such as hypertension, dyslipidemia, and abdominal obesity, may
contribute to these disparities (56). Testosterone has been
implicated in promoting atherogenic lipid profiles,
insulin resistance, and proinflammatory states, predisposing
men to an increased risk of CAD.
Conversely,
women typically present with CVD at older ages and often exhibit different
clinical manifes- tations
compared to men (57). Women are more likely to present with atypical
symptoms of ischemic heart disease, such as fatigue, dyspnea, and abdominal
discomfort, leading to diagnostic challenges and delays in treatment
initiation. Additionally, hormonal factors, including estrogen deficiency
post-menopause, play a pivotal role in the pathogenesis of CVD in women (58).
Estrogen exerts vasoprotective effects by promoting
vasodilation, inhibiting vascular inflammation, and attenuating
atherosclerosis, thus conferring cardiovas- cular benefits to premenopausal women.
The
interplay betweensexhormones andtraditional
cardiovascular risk factors further contributes to gender differences in CVD.
Estrogen has been shown to modulate lipid metabolism, glucose homeostasis, and
endothelial function, thereby reducing the risk of CAD in premenopausal women (59).
However, with the onset of menopause and the decline in estrogen levels, women
experience an accelerated progression of atherosclerosis and an increased risk
of CVD, highlighting the cardioprotective effects of
estrogen.
Understanding
the complex interplay between gender, sex hormones, and cardiovascular risk
factors is essential for developing targeted prevention and treatment
strategies for CVD. In the subsequent section, we will delve into the emerging
role of sex hormone-based therapies and personalized medicine approaches in
addressing gender-specific cardiovascular risk factors, further optimizing
cardiovascular outcomes for both men and women.
Cardiovascular
health in transgender individuals
The
cardiovascular health of transgender individuals is an emerging area of
research that has garnered increasing attention in recent years.
Gender-affirming hormone therapy (GAHT), a cornerstone of gender transition for
many transgender individuals, exerts profound effects on cardiovascular risk
factors and outcomes (60). Transgender women (assigned male at
birth) undergoing feminizing hormone therapy typically receive estrogen and
anti-androgen medications to induce physical and physiological changes
consistent with their gender identity (61). Conversely, transgender
men (assigned female at birth) undergoing masculinizing hormone therapy often
receive testosterone to promote virilization and
suppress feminizing characteristics.
The
impact of GAHT on cardiovascular health in transgender individuals is
multifaceted and influenced by various factors, including the type, dose, and
duration of hormone therapy, as well as baseline cardiovascular risk factors
and individual characteristics (62). Estrogen therapy in transgender
women has been associated with favorable changes in lipid profiles, including
reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C),
and triglycerides, although the effects on high-density lipoprotein cholesterol
(HDL-C) are less consistent (63). Estrogen also exerts vasoprotective effects by improving endothelial function,
reducing arterial stiffness, and attenuating inflammation, potentially lowering
the risk of cardiovascular events. Conversely, testosterone therapy in
transgender men has been linked to adverse changes in lipid metabolism, including
increases in total cholesterol, LDL-C, and triglycerides, and decreases in
HDL-C, predisposing individuals to a higher risk of atherosclerosis and
cardiovascular disease. Testosterone therapy may also exacerbate other
cardiovascular risk factors, such as insulin resistance, hypertension, and
central adiposity, particularly in individuals predisposed to metabolic
syndrome (64).
Despite
these considerations, cardiovascular risk assessment and management in
transgender individuals remain challenging due to limited research and clinical
guidelines specific to this population (65). Clinicians caring for
transgender patients should conduct comprehensive cardiovascular risk
assessments, including evaluation of traditional risk factors, lipid profiles,
blood pressure, and lifestyle factors. Shared decision-making between patients
and providers is crucial in determining the appropriateness of GAHT and
mitigating potential cardiovascular risks through lifestyle modifications,
pharmacological interventions, and close monitoring (66).
As
research in this field continues to evolve, there is a pressing need for
prospective studies to elucidate the long-term cardiovascular effects of GAHT
in transgender individuals and inform evidence-based guidelines for cardiovascular
risk assessment and management in this population. In the subsequent section,
we will explore emerging research findings and clinical considerations
regarding cardiovascular health in transgender individuals, shedding light on
potential avenues for improving cardiovascular outcomes in this marginalized
population.
Future
directions and therapeutic implications
Advancements
in understanding the intricate interplay between sex hormones and
cardiovascular health have paved the way for novel therapeutic interventions
and personalized medicine approaches aimed at optimizing cardiovascular
outcomes. Future directions in this field encompass the exploration of
potential new therapies targeting sex hormone pathways, the implementation of
personalized medicine approaches considering hormonal status, and the
identification of key areas for future research.
One
promising avenue for future research lies in the development of novel therapies
that selectively target sex hormone pathways to modulate cardiovascular risk
factors and outcomes. Emerging evidence suggests that agents targeting estrogen
and androgen receptors, such as selective estrogen receptor modulators (SERMs)
and selective androgen receptor modulators (SARMs) hold promise for the
prevention and treatment of cardiovascular diseases. These agents offer the
potential for more targeted and precise modulation of sex hormone signaling
pathways, minimizing off-target effects and optimizing therapeutic efficacy.
Furthermore,
personalized medicine approaches that take into account an individual's
hormonal status and cardiovascular risk profile are poised to revolutionize
cardiovascular care. Tailoring treatment strategies based on the specific
hormonal milieu and cardiovascular risk factors of each patient can enhance the
effectiveness of interventions and improve clinical outcomes. Biomarkers
indicative of sex hormone levels, vascular function, and inflammation may serve
as valuable tools for risk stratification and treatment selection, enabling
clinicians to deliver more personalized and precise care to transgender
individuals and patients with hormone-related cardiovascular disorders.
In
addition to therapeutic interventions, future research efforts should focus on
elucidating unanswered questions and addressing knowledge gaps in the field of
sex hormones and cardiovascular health. Longitudinal studies are needed to
investigate the long-term cardiovascular effects of gender-affirming hormone
therapy in transgender individuals, including the impact on cardiovascular
events, mortality, and quality of life. Furthermore, mechanistic studies
exploring the underlying pathways through which sex hormones influence
cardiovascular physiology and pathophysiology are essential for identifying
novel therapeutic targets and developing targeted interventions.
Overall,
the integration of innovative therapeutic approaches, personalized medicine
strategies, and rigorous research endeavors holds immense promise for advancing
our understanding of the complex interplay between sex hormones and
cardiovascular health, ultimately leading to improved outcomes for individuals
at risk for or affected by hormone-related cardiovascular disorders.
Conclusiones
In
conclusion, the intricate interplay between sex hormones and cardiovascular
health underscores the importance of tailored approaches to risk assessment,
management, and therapeutic interventions. While significant strides have been
made in elucidating the mechanisms underlying hormonal influences on
cardiovascular physiology, numerous opportunities for further research and
clinical innovation remain.
Moving
forward, the integration of personalized medicine strategies, novel therapeutic
modalities targeting sex hormone pathways, and rigorous longitudinal studies
are essential for optimizing cardiovascular outcomes in diverse populations,
including transgender individuals and those affected by hormone-related
cardiovascular disorders. By advancing our understanding of these complex
interactions, we can strive towards more effective prevention, treatment, and
management of cardio- vascular diseases, ultimately enhancing the health and
well-being of individuals across the gender spectrum.
REFERENCES
1. Roth
GA, Johnson C, Abajobir A, et al. Global, Regional,
and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J
Am Coll Cardiol.
2017;70(1):1-25. doi:10.1016/j. jacc.2017.04.052.
2. Maas
AHEM, Rosano G, Cifkova R,
et al. Cardiovascular health after menopause transition, in the context of the
ESHRE 2020 guidelines on endometriosis and reproductive health. Eur Heart J. 2021;42(27):2725-2733. doi:10.1093/eurheartj/ ehab273.
3. Toth PP, Banach M. Statin therapy
in postmenopausal women: A comprehensive review. Curr
Atheroscler Rep. 2021;23(1):3.
doi:10.1007/s11883-020-00908-1.
4. Filardo G, Hasselblad V, Dickersin
K, et al. Progesterone for preventing preterm birth. Cochrane Database Syst Rev. 2020;1(1). doi:
10.1002/14651858.CD004947.pub4.
5. Rosano GMC, Sheiban I, Massaro R, et al. Low testosterone levels in men with
coronary artery disease: pathophysiological mechanisms and potential
therapeutic implications. J Clin Endocrinol
Metab. 2020;105(4). doi:10.1210/clinem/dgaa132.
6. Wang
Y, Dean JL, Millar MR, et al. Functional analysis of novel androgen-responsive
genes in prostate cancer cells identified by cDNA microarray profiling. J Biol Chem. 2004;279(38):31879-31887.
doi:10.1074/jbc.M402878200.
7.
Boardman HM, Hartley L, Eisinga A, et al. Hormone
therapy for preventing cardiovascular disease in post-menopausal women.
Cochrane Database Syst Rev. 2020;(3). doi: 10.1002/14651858.CD002229.pub5.
8.
Virani SS, Alonso A, Aparicio HJ, et al. Heart
disease and stroke statistics-2021 update. Circulation. 2021. 10.1161/
CIR.0000000000000950 [PubMed]
9. Kopp
W. How Western diet and lifestyle drive the pandemic of obesity and
civilization diseases. Diabetes, Metab Syndr Obes Targets Ther. 2019;12:2221–2236. doi: 10.2147/DMSO. S216791.
10. Oneglia A, Nelson MD, Merz CNB.
Sex differences in cardiovascular aging and heart failure. Curr
Heart Fail Rep. 2020; 17:409–423. doi:
10.1007/s11897-020-00487-7.
11. Lam CSP, Arnott
C, Beale AL, Chandramouli C, Hilfiker-Kleiner
D, Kaye DM, Ky B, Santema
BT, Sliwa K, Voors AA. Sex
differences in heart failure. Eur Heart J. 2019; 40:
3859–3868c. Comprehensive overview of how heart failure progression and
symptoms differ between men and women.
12. Dewan P, Rørth R, Jhund PS, et al. Differential impact of heart failure with
reduced ejection fraction on men and women. J Am Coll
Cardiol. 2019;73:29–40. doi: 10.1016/j. jacc.2018.09.081.
13. Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF
and HFrEF. JACC Hear Fail. 2018;6:701–709.
doi: 10.1016/j. jchf.2018.05.018.
14. Chen X, Savarese G, Dahlström U, Lund LH,
Fu M. Age-dependent differences in clinical phenotype and prognosis in heart
failure with mid-range ejection compared with heart failure with reduced or
preserved ejection fraction. Clin Res Cardiol. 2019;108:1394–1405. doi: 10.1007/s00392-019-01477-z.
15. Santema BT, Ouwerkerk W, Tromp J,
et al. Identifying optimal doses of heart failure medications in men compared
with women: a prospective, observational, cohort study. Lancet. 2019;394:1254–1263. doi:
10.1016/S0140-6736(19)31792-1.
16. Shi W, Sheng X,
Dorr KM, et al. Cardiac proteomics reveals sex chromosome-dependent differences
between males and females that arise prior to gonad formation. Dev Cell. 2021;56:3019–3034.e7. doi:
10.1016/j.devcel.2021.09.022.
17. El Khoudary SR, Aggarwal B, Beckie
TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA. Menopause
transition and cardiovascular disease risk: implications for timing of early
prevention: a scientific statement from the American Heart Association.
Circulation. 2020. 10.1161/CIR.0000000000000912. Current advice and statement
by the American Heart Association on Cardiovascular risk related to menopause.
18. Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct
Biol. 2019;116:135–170. doi:
10.1016/bs.apcsb.2019.01.001.
19. Chistiakov DA, Myasoedova
VA, Melnichenko AA, Grechko
AV, Orekhov AN. Role
of androgens in cardiovascular pathology. Vasc Heal
Risk Manag. 2018;14:283–290.
doi: 10.2147/VHRM.S173259.
20. Barrientos G,
Llanos P, Basualto-Alarcon C, Estrada M.
Androgen-regulated cardiac metabolism in aging men. Front Endocrinol.
2020;11:316. doi:
10.3389/fendo.2020.00316.
21. Vanh K, Liu J. Differential effects of progestogens used
for menopausal hormone therapy. Clin Obs Gynecol. 2018;61:454–462. doi: 10.1097/GRF.0000000000000364.
22. Ferreira C, Trindade F, Ferreira R, Neves JS,
Leite-Moreira A, Amado F, Santos M, Nogueira-Ferreira R (2021) Sexual dimorphism in cardiac
remodeling: the molecular mechanisms ruled by sex hormones in the heart. J Mol Med. 2021. 10.1007/s00109-021-02169-w. Recently
published roadmap towards the development of sex-specific therapeutic
approaches.
23. Pedroza DA, Subramani R, Lakshmanaswamy R. Classical and non-classical progesterone
signaling in breast cancers. Cancers (Basel). 2020. 10.3390/cancers12092440.
24. Sickinghe AA, Korporaal SJA, den Ruijter HM, Kessler EL (2019) Estrogen contributions to
microvascular dysfunction evolving to heart failure with preserved ejection
fraction. Front Endocrinol. 2019;10:442.
Relevant overview pertaining to estrogen-related effects in patients with heart
failure with preserved ejection fraction.
25. Cruz-Topete D, Dominic P, Stokes KY. Uncovering sex-specific
mechanisms of action of testosterone and redox balance. Redox Biol. 2020;31:101490. doi:
10.1016/j.redox.2020.101490.
26. Dai Q, Likes
CE, 3rd, Luz AL, Mao L, Yeh JS, Wei Z, Kuchibhatla M, Ilkayeva OR, Koves TR, Price TM. A mitochondrial
progesterone receptor increases cardiac beta-oxidation and remodeling. J Endocr Soc. 2019;3:446–467. doi: 10.1210/ js.2018-00219.
27. Lan C, Cao N,
Chen C, et al. Progesterone, via yes-associated protein, promotes cardiomyocyte proliferation and cardiac repair. Cell Prolif. 2020;53:e12910.
28. You Y, Tan W, Guo Y, Luo M, Shang FF, Xia Y, Luo S. Progesterone promotes
endothelial nitric oxide synthase expression through enhancing nuclear
progesterone receptor-SP-1 formation. Am J Physiol
Hear Circ Physiol. 2020;319:H341H348. doi: 10.1152/ajpheart.00206.2020.
29. Pang Y, Thomas
P. Involvement of sarco/endoplasmic reticulum Ca
(2+)-ATPase (SERCA) in mPRalpha (PAQR7)-mediated progesterone induction of
vascular smooth muscle relaxation. Am J Physiol Endocrinol Metab. 2021;320:E453–E466. doi:
10.1152/ajpendo.00359.2020.
30. Spaziani M, Radicioni AF
Metabolic and cardiovascular risk factors in Klinefelter
syndrome. Am J Med Genet C Semin Med Genet. 2020;184:334–343. Overview of cardiovascular effects of
androgen deficiencies relevant to the current article.
31. Pizzocaro A, Vena W, Condorelli R, et al. Testosterone
treatment in male patients with Klinefelter syndrome:
a systematic review and meta-analysis. J Endocrinol
Invest. 2020;43:1675–1687. doi:
10.1007/s40618-020-01299-1.
32. Martinez C, Rikhi R, Haque T, Fazal A, Kolber M, Hurwitz BE, Schneiderman N, Brown TT. Gender identity, hormone therapy,
and cardiovascular disease risk. Curr Probl Cardiol. 2020;45:100396.
doi: 10.1016/j.cpcardiol.2018.09.003.
33. Gagliano-Jucá T, Basaria S.
Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019;16:555–574.
Extensive overview testosterone-based therapies and cardiovascular effects.
34. Zhao D, Guallar
E, Ballantyne CM, et al. Sex hormones and incident heart failure
in men and postmenopausal women: the atherosclerosis risk in communities study.
J Clin Endocrinol Metab. 2020. 10.1210/clinem/dgaa500.
35. Verdonschot JAJ, Hazebroek MR, Krapels IPC, et al. Implications of genetic testing in
dilated cardiomyopathy. Circ Genom
Precis Med. 2020. 10.1161/CIRCGEN.120.003031. Demonstration of how genetic
predisposition is not always reflected in heart failure–related symptoms and
the importance of genetic screening to improve personalized medicine.
36. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic
variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140:31–41. doi:
10.1161/CIRCULATIONAHA.118.037934.
37. de Blok CJ, Wiepjes CM, van Velzen DM, Staphorsius AS, Nota NM, Gooren
LJ, Kreukels BP, den Heijer
M. Mortality trends over five decades in adult transgender people receiving
hormone treatment: a report from the Amsterdam cohort of gender dysphoria.
Lancet Diabetes Endocrinol. 2021; 9:663–670. doi: 10.1016/S2213-8587(21)00185-6.
38. Streed CG, Beach LB, Caceres BA, Dowshen
NL, Moreau KL, Mukherjee M, Poteat T, Radix A, Reisner SL, Singh V; American Heart Association Council on
Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular
Biology; Council on Cardiovascular and Stroke Nursing; Council on
Cardiovascular Radiology and Intervention; Council on Hypertension; and Stroke
Council. Assessing and addressing cardiovascular health in people who are
transgender and gender diverse: a scientific statement from the American Heart Association.Circulation. 2021; 144: e136– e148. doi: 10.1161/CIR.0000000000001003.
39. Obstetricians
AC, Gynecologists, Practice CG, Obstetricians AC, Gynecologists, Women CHCU.
Health care for transgender and gender diverse individuals: ACOG committee
opinion, number 823.Obstet Gynecol. 2021; 137:e75–e88.
40. Moreira Allgayer RMC, Borba GDS, Moraes RS, Ramos RB, Spritzer PM. The
effect of gender-affirming hormone therapy on the risk of subclinical atherosclerosis
in the transgender population: a systematic review.Endocr Pract. 2023;
29:498–507. doi: 10.1016/j.eprac.2022.12.017.
41. Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig
MS. Blood pressure effects of gender-affirming hormone therapy in transgender
and gender-diverse adults.Hypertension.
2021; 77:2066–2074. doi: 10.1161/HYPERTENSIONA-
HA.120.16839.
42. Reckelhoff JF, Shawky NM, Romero
DG, Yanes Cardozo LL. Polycystic ovary syndrome:
insights from pre-clinical research.Kidney
360. 2022; 3:1449–14571449–1457. doi: 10.34067/
KID.0002052022.
43. Shawky NM, Patil CN, Dalmasso C, Maranon RO, Romero DG, Drummond H, Reckelhoff JF. Pregnancy protects hyperandrogenemic
female rats from postmenopausal hypertension.Hypertension.
2020; 76:943–952. doi: 10.1161/HYPER-
TENSIONAHA.120.15504.
44. Chen J, Yu J,
Yuan R, Li N, Li C, Zhang X. mTOR inhibitor improves
testosterone-induced myocardial hypertrophy in hypertensive rats.J Endocrinol. 2022;
252:179–193. doi: 10.1530/JOE-21-0284.
45. Lichtenecker DCK, Argeri R,
Castro CHM, Dias-da-Silva MR, Gomes GN. Cross-sex testosterone therapy modifies
the renal morphology and function in female rats and might underlie increased
systolic pressure.Clin Exp Pharmacol Physi-
ol. 2021; 48:978–986. doi:
10.1111/1440-1681.13495.
46. Santos JD,
Oliveira-Neto JT, Barros PR, Damasceno
LEA, Lautherbach N, Assis AP, Silva CAA, Sorgi CA, Faccioli LH, Kettelhut IC, et al. Th17 cell-linked mechanisms mediate
vascular dysfunction induced by testosterone in a mouse model of gender-affirming
hormone therapy.Am J Physiol Heart Circ Physiol. 2022;
323:H322–H335. doi: 10.1152/ ajpheart.00182.2022.
47. Bartels CB, Uliasz TF, Lestz L, Mehlmann LM. Short-term testosterone use in female mice
does not impair fertilizability of eggs: implications
for the fertility care of transgender males.
HumReprod.2021;36:189–198.doi:10.1093/humrep/deaa282.
48. Kinnear HM, Hashim PH, Dela Cruz C, Chang FL,
Rubenstein G, Nimmagadda L, Elangovan
VR, Jones A, Brunette MA, Hannum DF, et al. Presence
of ovarian stromal aberrations after cessation of testosterone therapy in a
transgender mouse model.Biol
Reprod. 2023; 108:802–813. doi:
10.1093/ biolre/ioad019.
49. Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S. Anti-androgenic effects comparison be-
tween cyproterone acetate and spironolactone in transgen- der women: a randomized controlled trial.J Sex Med. 2021;
18:1299–1307. doi: 10.1016/j.jsxm.2021.05.003.
50. Lee KS, Zhang
JJY, Kirollos R, Santarius
T, Nga VDW, Yeo TT. A systematic review and
meta-analysis of the association between cyproterone
acetate and intracranial meningiomas.Sci
Rep. 2022; 12:1942. doi: 10.1038/s41598-022- 05773-z.
51. Forster RB, Engeland A, Kvåle R, Hjellvik V, Bjørge T. Association
between medical androgen deprivation therapy and long-term cardiovascular
disease and all-cause mortality in nonmetastatic
prostate cancer.Int J
Cancer. 2022; 151:1109– 1119. doi: 10.1002/ijc.34058.
52. Kokorovic A, So AI, Serag H,
French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, et al. UPDATE - Canadian Urological Association
guideline on androgen deprivation therapy: adverse events and management
strategies. Can Urol Assoc
J. 2022; 16:E416–E431. doi:
10.5489/cuaj.8054.
53. Malhotra A, Kort S, Lauther T, Mann N, Skopicki HA, Parikh PB. Prevalence and predictors of
cardiovascular disease and risk factors in transgender persons in the united states.Crit Pathw
Cardiol. 2022; 21:42–46. doi:
10.1097/ HPC.0000000000000271.
54. Totaro M, Palazzi S, Castellini
C, Parisi A, D’Amato F, Tienfor-
ti D, Baroni MG, Francavilla S, Barbonetti A. Risk
of venous thromboembolism in transgender people undergoing hormone feminizing
therapy: a prevalence meta-analysis and meta-regression study.Front Endocrinol
(Lausanne). 2021; 12:741866. doi:
10.3389/fendo.2021.741866.
55. Martinez-Martin FJ, Kuzior
A, Hernandez-Lazaro A, de Leon-Durango
RJ, Rios-Gomez C, Santana-Ojeda B, Perez-Rivero JM, Fernandez-Trujillo-Comenge PM, Gonzalez-Diaz P,
Arnas-Leon C, et al. Incidence of hypertension in young transgender people after
a 5-year follow-up: association with gender-affirming hormonal therapy.Hypertens Res. 2023;
46:219–225. doi: 10.1038/s41440-022-01067-z.
56. Klaver M, van Velzen D, de Blok
C, Nota N, Wiepjes C, Defreyne
J, Schreiner T, Fisher A, Twisk J, Seidell J, et al. Change in visceral fat and total body fat
and the effect on cardiometabolic risk factors during
transgender hormone therapy.J
Clin Endocrinol Metab. 2022; 107:e153–e164. doi: 10.1210/clinem/dgab616.
57. Yun Y, Kim D, Lee ES. Effect of cross-sex hormones on body
composition, bone mineral density, and muscle strength in trans women.J Bone Metab.
2021; 28:59–66. doi: 10.11005/ jbm.2021.28.1.59.
58. Blackmore K,
Young CN. Central feminization of obese male mice reduces metabolic syndrome.Brain Sci. 2022; 12:1324.
doi: 10.3390/brainsci12101324.
59. Connelly PJ,
Clark A, Touyz RM, Delles
C. Transgender adults, gender-affirming hormone therapy and blood pressure: a
systematic review.J Hypertens. 2021; 39:223–230. doi:
10.1097/HJH.0000000000002632.
60. Njoroge JN, Tressel W, Biggs ML,
Matsumoto AM, Smith NL, Rosenberg E, Hirsch CH, Gottdiener
JS, Mukamal KJ, Kizer JR.
Circulating androgen concentrations and risk of incident heart failure in older
men: the Cardiovascular Health Study.J Am Heart
Assoc. 2022; 11:e026953. doi:
10.1161/ JAHA.122.026953.
61. Banga S, Heinze-Milne SD, Godin
J, Howlett SE. Signs of diastolic dysfunction are
graded by serum testosterone levels in aging C57BL/6 male mice.Mech Ageing Dev. 2021; 198:111523. doi: 10.1016/j.mad.2021.111523.
62. Yeap BB, Marriott RJ, Antonio L, Raj S, Dwivedi
G, Reid CM, Anawalt BD, Bhasin
S, Dobs AS, Handelsman DJ,
et al. Associations of serum testosterone and sex hormone-binding globulin with
incident cardiovascular events in middle-aged to older men.Ann Intern Med. 2022; 175:159–170. doi: 10.7326/M21-0551.
63. Khoudary SRE, Aggarwal B, Beckie
TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA. Menopause
transition and cardiovascular disease risk: implications for timing of early
prevention: a scientific statement from the American Heart Association.Circulation.
2020; 142:e506–e532. doi:
10.1161/CIR.0000000000000912.
64. Kim C, Saran R,
Hood M, Karvonen-Gutierrez C, Peng MQ, Randolph JFJ,
Harlow SD. Changes in kidney function during the menopausal transition: the
Study of Women’s Health Across the Nation (SWAN) – Michigan site.Menopause. 2020; 27:1066–1069. doi: 10.1097/GME.0000000000001579.
65. Zhu X, Tang Z,
Cong B. Selective estrogen receptor modulators: an updated review of clinical
applications and side effects. Cancer Manag Res. 2020;12:5857-5871. doi:10.2147/ CMAR.S278868.
66. Patel SM, Mavinkurve M, Menon DV. Cardiovascular risk prediction: The
old, the new, and the future. Methodist Debakey Cardiovasc J. 2020;16(3):e1-e7.
doi:10.14797/mdcj-16- 3-270.
Financing
No
funding
Conflicts
of interest
The author declare that they do not have any conflict of interest